NASDAQ: EQ - Equillium, Inc.

Altı ay boyunca karlılık: -57.13%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Equillium, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.

daha fazla ayrıntı
It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2018-10-11
ISIN US29446K1060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://equilliumbio.com
Цена ао 0.758
Günlük fiyat değişimi: -4.79% (0.4863)
Haftalık fiyat değişimi: -1.49% (0.47)
Aylık fiyat değişimi: -39.87% (0.77)
3 ayda fiyat değişimi: -33.86% (0.7)
Altı ayda fiyat değişimi: -57.13% (1.08)
Yıllık fiyat değişimi: -74.13% (1.79)
3 yılda fiyat değişimi: -85.02% (3.09)
5 yılda fiyat değişimi: -88.25% (3.94)
Yılbaşından bu yana fiyat değişimi: -38.12% (0.7482)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0.6101 10
P/BV 0.9753 9
P/E 0 0
EV/EBITDA 0.0261 10
Toplam: 6.13

Yeterlik

İsim Anlam Seviye
ROA, % -26.39 0
ROE, % -59.08 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0572 10
Toplam: 9

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 128.97 10
karlılık Ebitda, % -54.54 0
karlılık EPS, % -73.88 0
Toplam: 2
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Decheng Capital Management III (Cayman), LLC 4447308 12.61
Decheng Capital LLC 4447308 12.61
Vanguard Group Inc 836930 2.37
Cota Capital Management, LLC 562278 1.59
Tang Capital Management, LLC 400000 1.13
JP Morgan Chase & Company 350031 0.99
Renaissance Technologies, LLC 347500 0.99
Geode Capital Management, LLC 172387 0.49
Commonwealth Equity Services, LLC 100000 0.28
Callan Capital LLC 99688 0.28



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Daniel Mark Bradbury Executive Chairman 158k 1961 (64 yıl)
Mr. Bruce D. Steel C.F.A. Co-Founder, President, CEO & Director 779.87k 1966 (59 yıllar)
Ms. Christine Zedelmayer M.B.A., P.M.P. Senior VP & COO 553.73k 1970 (55 yıllar)
Dr. Stephen Connelly Ph.D. Chief Scientific Officer & Director 571.32k 1982 (43 yıl)
Mr. Jason A. Keyes Chief Financial Officer N/A 1971 (54 yıl)
Mr. Michael Moore Vice President of Investor Relations & Corporate Communications N/A
Dr. Matthew Ritter Ph.D. Senior Vice President of Corporate Development N/A
Mr. Joel M. Rothman Chief Development Officer N/A 1969 (56 yıllar)
Penny Tom Senior VP of Finance & Principal Accounting Officer N/A

Adres: United States, La Jolla. CA, 2223 Avenida De La Playa - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://equilliumbio.com